Scott Adams Appeals to Donald Trump for Help Accessing Life-Saving Cancer Drug Pluvicto

Dilbert creator Scott Adams has made a public appeal to former U.S. President Donald Trump for help securing access to Pluvicto, a critical FDA-approved cancer medication. Adams revealed that his healthcare provider has delayed the scheduling of the treatment, despite prior approval, and said his health is deteriorating rapidly due to metastatic prostate cancer. The plea comes months after Trump reportedly offered personal assistance during a phone conversation in May.

Trump quickly responded to the request on his social media platform Truth Social, assuring Adams that he was “on it.” Several of Trump’s political allies and former administration officials, including Health Secretary Robert F. Kennedy Jr. and Dan Scavino Jr., also reacted to the situation. Scavino confirmed that multiple officials were monitoring Adams’ case closely, while Donald Trump Jr. shared the post and promised to ensure his father saw the message, offering prayers for Adams’ recovery. According to Reuters, such rapid, high-level responses to individual medical appeals are highly uncommon.

Pluvicto, approved by the U.S. Food and Drug Administration in 2022, is a radioligand therapy used to treat advanced prostate cancer carrying the PSMA biomarker. It delivers targeted radiation directly to cancer cells while minimizing damage to surrounding tissue. Adams’ provider, Kaiser Permanente of Northern California, had initially authorized the therapy, but a breakdown in scheduling the intravenous administration reportedly stalled the process. Experts warn that such delays can have a serious impact on treatment timelines and patient outcomes.

For patients suffering from metastatic castration-resistant prostate cancer, treatment options are often limited, making timely access to Pluvicto critical. Adams’ case underscores ongoing challenges in the U.S. healthcare system, where bureaucratic hurdles can prevent even insured patients from receiving approved therapies. His public appeal highlights the lengths patients may go to secure life-saving care and could bring renewed attention to the broader issue of treatment access in America’s healthcare landscape.